TW202340243A - 抗cd39抗體及其用途 - Google Patents
抗cd39抗體及其用途 Download PDFInfo
- Publication number
- TW202340243A TW202340243A TW112107685A TW112107685A TW202340243A TW 202340243 A TW202340243 A TW 202340243A TW 112107685 A TW112107685 A TW 112107685A TW 112107685 A TW112107685 A TW 112107685A TW 202340243 A TW202340243 A TW 202340243A
- Authority
- TW
- Taiwan
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| WOPCT/CN2022/079021 | 2022-03-03 | ||
| PCT/CN2022/079021 WO2023164872A1 (en) | 2022-03-03 | 2022-03-03 | Anti-cd39 antibodies and use thereof |
| CN2022126070 | 2022-10-19 | ||
| WOPCT/CN2022/126070 | 2022-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202340243A true TW202340243A (zh) | 2023-10-16 |
Family
ID=87883061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112107685A TW202340243A (zh) | 2022-03-03 | 2023-03-02 | 抗cd39抗體及其用途 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11970543B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4486785A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7712496B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240156633A (cg-RX-API-DMAC7.html) |
| CN (2) | CN119173535A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128688A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023227964A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3253669A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002620A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315351A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024010646A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202340243A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023165561A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260191954A1 (en) * | 2022-12-01 | 2026-07-09 | Innate Pharma | Compositions and methods for neoadjuvant treatment in cancer |
| CN119798442B (zh) * | 2023-12-27 | 2025-12-16 | 华润生物医药有限公司 | 特异性结合cd39的纳米抗体及其用途 |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3153526B1 (en) | 2008-01-31 | 2020-09-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| WO2012085132A1 (en) | 2010-12-22 | 2012-06-28 | Orega Biotech | Antibodies against human cd39 and use thereof |
| US10556959B2 (en) * | 2014-11-07 | 2020-02-11 | Xencor, Inc. | Anti-CD39 antibodies and uses thereof |
| EP3380519A1 (en) | 2015-11-23 | 2018-10-03 | Innate Pharma | Cd39 vascular isoform targeting agents |
| WO2017157948A1 (en) | 2016-03-14 | 2017-09-21 | Innate Pharma | Anti-cd39 antibodies |
| US11376269B2 (en) | 2016-05-06 | 2022-07-05 | Inserm | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (AML) |
| WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
| AU2018235092B2 (en) | 2017-03-16 | 2024-09-19 | Innate Pharma | Compositions and methods for treating cancer |
| SG11202000820PA (en) | 2017-07-31 | 2020-02-27 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| AU2018346447B2 (en) | 2017-10-06 | 2025-06-19 | Innate Pharma | Restoration of T cell activity via the CD39/CD73 axis |
| IL273440B1 (en) | 2017-11-15 | 2026-08-01 | Innate Pharma | Strengthening the effect of ATP release |
| CN113754768B (zh) | 2018-03-14 | 2023-01-06 | 表面肿瘤学公司 | 结合cd39的抗体及其用途 |
| EP3806902A4 (en) | 2018-06-14 | 2022-05-04 | Beth Israel Deaconess Medical Center, Inc. | COMPOSITIONS AND METHODS TO PREVENT OR REVERSE T-CELL DEPLETION BY ECTONUCLEOTIDASE INHIBITION AND ANTIBODY-MEDIATED TARGET CYTOSIS |
| TWI870353B (zh) | 2018-06-18 | 2025-01-21 | 法商天賜製藥公司 | 用於治療癌症之組合物及方法 |
| MX2021010119A (es) | 2019-02-21 | 2021-12-10 | Trishula Therapeutics Inc | Tratamiento combinado con anticuerpos anti-cd39 y anticuerpos anti-pd1 o anti-pd-l1. |
| CN114127121B (zh) | 2019-08-12 | 2025-04-11 | 北京恩瑞尼生物科技股份有限公司 | 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物 |
| KR20220050971A (ko) * | 2019-08-27 | 2022-04-25 | 엘피사이언스 (쑤저우) 바이오파마, 엘티디. | 신규 항-cd39 항체 |
| KR20220062500A (ko) | 2019-09-16 | 2022-05-17 | 서피스 온콜로지, 인크. | 항-cd39 항체 조성물 및 방법 |
| CN110407941B (zh) | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| US12391756B2 (en) | 2019-11-05 | 2025-08-19 | Jacobio Pharmaceuticals Co., Ltd. | Binding molecule specific for CD39 and use thereof |
| WO2021203058A2 (en) | 2020-04-03 | 2021-10-07 | Trishula Therapeutics, Inc. | Combination therapy involving anti-cd39 antibodies and adoptive cell therapy |
| US20240052061A1 (en) | 2020-09-10 | 2024-02-15 | Purinomia Biotech, Inc. | Methods and compositions for potentiating antitumoral immune responses through targeting of ntpdase3 |
| EP4251650A4 (en) | 2020-11-27 | 2024-10-23 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfbeta |
-
2023
- 2023-03-02 TW TW112107685A patent/TW202340243A/zh unknown
- 2023-03-02 IL IL315351A patent/IL315351A/en unknown
- 2023-03-02 CA CA3253669A patent/CA3253669A1/en active Pending
- 2023-03-02 JP JP2024552127A patent/JP7712496B2/ja active Active
- 2023-03-02 AR ARP230100529A patent/AR128688A1/es unknown
- 2023-03-02 CN CN202380024645.6A patent/CN119173535A/zh active Pending
- 2023-03-02 WO PCT/CN2023/079295 patent/WO2023165561A1/en not_active Ceased
- 2023-03-02 MX MX2024010646A patent/MX2024010646A/es unknown
- 2023-03-02 KR KR1020247032745A patent/KR20240156633A/ko active Pending
- 2023-03-02 EP EP23762959.7A patent/EP4486785A4/en active Pending
- 2023-03-02 US US18/177,729 patent/US11970543B2/en active Active
- 2023-03-02 CN CN202411518282.4A patent/CN119569881B/zh active Active
- 2023-03-02 AU AU2023227964A patent/AU2023227964A1/en active Pending
-
2024
- 2024-03-25 US US18/616,056 patent/US20250084178A1/en active Pending
- 2024-09-02 CL CL2024002620A patent/CL2024002620A1/es unknown
-
2025
- 2025-07-10 JP JP2025116414A patent/JP2025148452A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3253669A1 (en) | 2023-09-07 |
| IL315351A (en) | 2024-11-01 |
| CN119569881A (zh) | 2025-03-07 |
| US20240034803A1 (en) | 2024-02-01 |
| AU2023227964A1 (en) | 2024-09-19 |
| JP2025508956A (ja) | 2025-04-10 |
| CN119173535A (zh) | 2024-12-20 |
| US11970543B2 (en) | 2024-04-30 |
| JP2025148452A (ja) | 2025-10-07 |
| WO2023165561A1 (en) | 2023-09-07 |
| EP4486785A1 (en) | 2025-01-08 |
| CN119569881B (zh) | 2025-11-07 |
| KR20240156633A (ko) | 2024-10-30 |
| AR128688A1 (es) | 2024-06-05 |
| EP4486785A4 (en) | 2026-07-08 |
| JP7712496B2 (ja) | 2025-07-23 |
| CL2024002620A1 (es) | 2025-01-03 |
| MX2024010646A (es) | 2024-09-19 |
| US20250084178A1 (en) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11820824B2 (en) | Antibodies to TIGIT | |
| TWI791422B (zh) | 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合 | |
| AU2011278227B2 (en) | Superior efficacy of CD37 antibodies in CLL blood samples | |
| JP7712496B2 (ja) | 抗cd39抗体及びその使用 | |
| KR20220123105A (ko) | 항-갈렉틴-9 항체 및 그것의 용도 | |
| US20250179176A1 (en) | Anti-tigit antibodies and uses of the same | |
| KR20240058149A (ko) | Vista 항원-결합 분자를 사용한 암의 치료 및 예방 | |
| WO2023164872A1 (en) | Anti-cd39 antibodies and use thereof | |
| HK40124330A (en) | Anti-cd39 antibodies and use thereof | |
| HK40124330B (en) | Anti-cd39 antibodies and use thereof | |
| HK40113788A (en) | Anti-cd39 antibodies and use thereof | |
| CN114630679A (zh) | 抗garp抗体和免疫调节剂的组合 | |
| JP2022554270A (ja) | 抗pd-1抗体による癌を治療する方法 | |
| TW202241511A (zh) | 新穎抗體組合及其用途 | |
| HK40095521A (en) | Novel combinations of antibodies and uses thereof | |
| HK40091842A (en) | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment | |
| HK40122875A (en) | Anti-tigit antibodies and uses of the same | |
| HK40079159A (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| HK1260737A1 (en) | Novel anti-pd-l1 antibodies |